The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years entered that market. Using primary research from U.S. cardiologists, primary care physicians, and managed care organization medical/pharmacy directors, this content examines market access factors in the United States. Understanding the interaction between payers and physicians, including the impact of reimbursement decisions on the prescribing and uptake of therapies at the brand level, will help unravel treatment drivers in this indication.
- Heart Failure - Access & Reimbursement - Detailed, Expanded Analysis Chronic Heart Failure (US)
Author(s): Dominika Rudnicka-Noulin, PhD, MSc
Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.
Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions